Glimberg M2 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 1000 mg in a sustained-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients whose blood glucose levels are inadequately controlled by diet, exercise, and monotherapy with either agent alone. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The sustained-release formulation allows for a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Glimberg M2 Forte should be used as part of a comprehensive diabetes management plan that includes dietary modifications and regular physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and lactic acid levels is recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerability to minimize the risk of hypoglycemia and other adverse effects.